COAG Earnings Results and History
Hemab Therapeutics Holdings, Inc.'s earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.
- EPS−$0.58 vs −$0.50 est −15.6%
- Revenue–
Filed ยท Press release
Key takeaways
from the press release- Net loss widened to $27.3 million, or $0.58 per share, from $17.1 million a year earlier.
- R&D expenses rose to $24.6 million from $14.6 million as clinical programs advanced and headcount grew.
Filings and dates
SEC EDGAR- Feb 9, 2027Next earnings reportexpected
- Nov 10, 2026Earnings release, Q3 20268-K Press release
Also see COAG institutional ownership and the earnings calendar.
COAG earnings FAQ
What were COAG's latest earnings?
For Q3 2026 Hemab Therapeutics Holdings, Inc. reported, GAAP EPS of -$0.58. The results were filed with the SEC on Nov 10, 2026.
When is COAG's next earnings date?
Hemab Therapeutics Holdings, Inc. is expected to report on Feb 9, 2027. Dates can move until the company confirms them.
Where do these numbers come from?
Results, guidance and financials come from Hemab Therapeutics Holdings, Inc.'s own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.